Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Eag1: an emerging oncological target.

Luis A Pardo1, Walter Stühmer

  • 1Max-Planck Institute of Experimental Medicine, Göttingen, Germany. pardo@em.mpg.de

Cancer Research
|March 15, 2008
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Mitochondria-Targeting Moieties Based on N-Tethered Pyridinium Cations.

Angewandte Chemie (International ed. in English)·2026
Same author

Microenvironmental acidosis drives PARP- and ATM inhibitor resistance in p53 deficient pancreatic cancer.

iScience·2026
Same author

pH-Dependent Microenvironmental Ionic Signaling in Pancreatic Ductal Adenocarcinoma.

Acta physiologica (Oxford, England)·2026
Same author

Correction: Preserved fascicular architecture predicts neuroma pain: a morphometric study.

Acta neuropathologica communications·2026
Same author

Hyperspectral Imaging Reveals High Water and Hemoglobin Content at Rest and Decreased Oxygen Levels After Physical Activity at the Residual Limb of Non-Dysvascular Lower Limb Amputees.

Microcirculation (New York, N.Y. : 1994)·2026
Same author

New mitochondrial K<sub>V</sub>1.3 conjugates are potent and specific inducers of apoptosis in cancer models.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie·2026
Same journal

CDK2 Inhibition Exerts RB-Independent Antitumor Activity in CDK4/6 Inhibitor-Resistant HR+/HER2- Breast Cancer.

Cancer research·2026
Same journal

A Clinically Integrated Pediatric Patient-Derived Xenograft Program Enables Evaluation of Cohort and Patient-Specific Biology and Therapeutic Strategies.

Cancer research·2026
Same journal

Editor's Note: Heterodimerization of Insulin-like Growth Factor Receptor/Epidermal Growth Factor Receptor and Induction of Survivin Expression Counteract the Antitumor Action of Erlotinib.

Cancer research·2026
Same journal

Editor's Note: Deguelin Analogue SH-1242 Inhibits Hsp90 Activity and Exerts Potent Anticancer Efficacy with Limited Neurotoxicity.

Cancer research·2026
Same journal

Retraction: Two Functional Epitopes of Pigment Epithelial-Derived Factor Block Angiogenesis and Induce Differentiation in Prostate Cancer.

Cancer research·2026
Same journal

Editor's Note: Chronic Stress Facilitates Lung Tumorigenesis by Promoting Exocytosis of IGF2 in Lung Epithelial Cells.

Cancer research·2026
See all related articles

The potassium channel Eag1 drives cancer progression. Inhibiting Eag1 with a monoclonal antibody restricts cancer cell proliferation, suggesting Eag1 as a therapeutic target for cancer treatment.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biophysics

Background:

  • Ion channels are increasingly recognized for roles beyond electrical signaling.
  • Their involvement in physiological and pathological processes, including cancer, is an active area of research.

Purpose of the Study:

  • To investigate the role of the potassium channel Eag1 in cancer progression.
  • To evaluate the therapeutic potential of targeting Eag1 in cancer treatment.

Main Methods:

  • Utilized a monoclonal antibody to inhibit Eag1 channel activity.
  • Assessed the impact of Eag1 inhibition on cancer cell proliferation.

Main Results:

  • The potassium channel Eag1 was found to mediate cancer progression.

Related Experiment Videos

  • Monoclonal antibody inhibition of Eag1 effectively restricted cancer cell proliferation.

    • Conclusions:

    • Eag1 channel activity is implicated in driving cancer progression.
    • Targeting Eag1 presents a potential diagnostic and therapeutic strategy for cancer.